Alissa Visram (A Visram, Donna Reece)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 20

Top Topics

Multiple Myeloma

Stem Cell Transplantation

Monoclonal Antibody

Acute Lymphoblastic Leukemia

Top Venues

Blood cancer journal

Nature medicine

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Alissa Visram, Celine M Vachon, Linda B Baughn, Dirk Larson, James Smadbeck, Angela Dispenzieri, Prashant Kapoor, Martha Q Lacy, Morie A Gertz, Francis K Buadi, Suzanne R Hayman, David Dingli, Taxiarchis V Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson R Leung, Robert A Kyle, S Vincent Rajkumar, Shaji K Kumar
Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia (2024)
Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Alissa Visram
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature medicine 30 (2) (2024)
Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Alissa Visram
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature medicine 30 (2) (2024)
Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Alissa Visram
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature medicine 30 (2) (2024)
Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Alissa Visram
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature medicine 30 (2) (2024)
Arleigh McCurdy, Alissa Visram, Martha L Louzada, Darrell White, Stephen Parkin, Michael P Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Suzanne Trudel
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial. Blood cancer journal 14 (1) (2024)
Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Alissa Visram
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature medicine (2024)
Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q Lacy, Morie A Gertz, Francis K Buadi, Suzanne R Hayman, David Dingli, Taxiarchis V Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson R Leung, Robert A Kyle, Shaji K Kumar
Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100. Leukemia (2024)
Arleigh McCurdy, Hira S Mian, Richard LeBlanc, Victor H Jimenez-Zepeda, Jiandong Su, Esther Masih-Khan, Alissa Visram, Martha Louzada, Kevin Song, Darrell White, Michael Sebag, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rami Kotb, Rayan Kaedbey, Engin Gul, Donna Reece, Christopher P Venner
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Blood cancer journal 13 (1) (2023)
Arleigh McCurdy, Hira S Mian, Richard LeBlanc, Victor H Jimenez-Zepeda, Jiandong Su, Esther Masih-Khan, Alissa Visram, Martha Louzada, Kevin Song, Darrell White, Michael Sebag, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rami Kotb, Rayan Kaedbey, Engin Gul, Donna Reece, Christopher P Venner
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Blood cancer journal 13 (1) (2023)
Alissa Visram, Hsien Seow, Mark A Fiala, Anastasia Gayowsky, Matthew C Cheung, Gwynivere Davies, Gregory R Pond, Hira S Mian
Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population-based cohort study. American journal of hematology (2023)
Alissa Visram, A De La Torre, D White, J Su, E Masih-Khan, M Chu, V Jimenez-Zepeda, Arleigh McCurdy, R LeBlanc, K Song, Hira S Mian, M Louzada, M Sebag, D Bergstrom, J Stakiw, A Reiman, R Kotb, M Aslam, C Venner, R Kaedbey, Engin Gul, D Reece
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database. Blood cancer journal 13 (1) (2023)
Richard LeBlanc, Hira S Mian, Donna Reece, Jiandong Su, Esther Masih-Khan, Michael Chu, Victor H Jimenez-Zepeda, Michael Sebag, Kevin Song, Martha Louzada, Rami Kotb, Alissa Visram, Darrell White, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rayan Kaedbey, Engin Gul, Christopher P Venner
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis. European journal of haematology (2023)
Alissa Visram, Suzanne R Hayman, Angela Dispenzieri, Prashant Kapoor, Martha Q Lacy, Morie A Gertz, Francis K Buadi, David Dingli, Rahma M Warsame, Taxiarchis V Kourelis, Joselle Madonna Cook, Moritz Binder, Wilson I Gonsalves, Eli Muchtar, Nelson R Leung, Vivek Roy, Sundararajan Vincent Rajkumar, Shaji K Kumar
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL). American journal of hematology (2023)
Joselle Madonna Cook, Wilson I Gonsalves, Morie A Gertz, Alissa Visram, Rahma Warsame, Martha Q Lacy, Angela Dispenzieri, David Dingli, Prashant Kapoor, Taxiarchis V Kourelis, Suzanne R Hayman, Robert A Kyle, Eli Muchtar, Shaji K Kumar, William Joseph Hogan, Eapen K Jacob, Francis K Buadi
Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone marrow transplantation 57 (6) (2022)
Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q Lacy, Morie A Gertz, Francis K Buadi, Suzanne R Hayman, David Dingli, Taxiarchis V Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson R Leung, Robert A Kyle, Shaji K Kumar
Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100. Leukemia 36 (5) (2022)
Arleigh McCurdy, Alissa Visram
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma. Current hematologic malignancy reports 17 (6) (2022)
Alissa Visram, C Soof, Sundararajan Vincent Rajkumar, Shaji K Kumar, S Bujarski, T M Spektor, R A Kyle, J R Berenson, Angela Dispenzieri
Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood cancer journal 11 (6) (2021)
Alissa Visram, Sundararajan Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q Lacy, Morie A Gertz, Francis K Buadi, Suzanne R Hayman, David Dingli, Taxiarchis V Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson R Leung, Linda B Baughn, Robert A Kyle, Shaji K Kumar
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood cancer journal 11 (11) (2021)
Alissa Visram, Celine M Vachon, Linda B Baughn, Dirk Larson, James Smadbeck, Angela Dispenzieri, Prashant Kapoor, Martha Q Lacy, Morie A Gertz, Francis K Buadi, Suzanne R Hayman, David Dingli, Taxiarchis V Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson R Leung, Robert A Kyle, S Vincent Rajkumar, Shaji K Kumar
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia (2021)